Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019 (European Urology)

On March 11, 2019--relatively unnoticed by the public and medical professionals--the European Commission (EC) implemented stringent regulatory conditions regarding the use of fluoroquinolones in urology. Fluoroquinolones (eg. ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, and ofloxacin) are the antimicrobial drugs most frequently used in urology and this legally binding decision is applicable in all EU countries. National authorities have been urged to enforce this ruling and to take all appropriate measures to promote the correct use of this class of antibiotics.